The American Journal of Managed Care

Study: Patients With SCD Report Discrimination Based on Race, Pain, and Other Factors

A new report based on patient focus groups suggests many clinicians can do more to help patients with sickle cell disease (SCD) feel heard and understood. People with sickle cell disease (SCD) say a ...
The American Journal of Managed Care

FDA Approves Exagamglogene Autotemcel, First CRISPR Gene-Editing Therapy for SCD

The FDA has approved the first clustered regularly interspaced short palindromic repeats (CRISPR) gene-editing therapy for use in patients with sickle cell disease (SCD). Exagamglogene autotemcel (exa ...
Business Wire

SCD-PROTECT publication: High SCD risk despite modern GDMT across 19,500+ LifeVest ® patients

81.7% of patients were on an SGLT2 inhibitor 74.7% of patients were on an ARNI 95.1% of patients were on a beta-blocker 83.1% of patients were on an MRA Despite high use of GDMT, the rate of ...
Medscape

Pfizer's Withdrawal of SCD Drug Raises Questions

The global withdrawal of voxelotor (Oxbryta, Pfizer) has left clinicians who treat sickle cell disease (SCD) with the urgent task of reaching patients taking the medicine, while trying to understand ...